Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs - Wikidata - awgldk - TriplyDB

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

http://www.wikidata.org/entity/Q36950813

about

Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment Amyloid diseases of the heart: current and future therapies Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis Updates in cardiac amyloidosis: a review.A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.New developments in conditioning regimens before auto-SCT in multiple myeloma.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.Light chain amyloidosis 2012: a new era.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?Immunoglobulin light chain amyloidosis.Not too little, not too much-just right! (Better ways to give high dose melphalan).Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Pathophysiology and treatment of cardiac amyloidosis.Recent advances in the management of AL Amyloidosis.Systemic amyloidosis: novel therapies and role of biomarkers.Newer Therapies for Amyloid Cardiomyopathy.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.Outcomes of patients with renal monoclonal immunoglobulin deposition disease.Cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis.How to manage primary amyloidosis.Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

P2860

Q26827340-59015E75-B24A-4B0A-A5B4-D001D69FE548 Q27023836-BCF470C5-4DDE-4C7E-833F-E167B8953031 Q28069975-33F205AC-A070-4CC3-9D6E-4F751989F967 Q34448455-F3BCFBE7-00B9-47B8-BAE7-285C545D23B6 Q36015183-8A723C1E-ABD3-4850-9406-84489F96B9C1 Q36163205-D3907D71-CFAD-4152-950E-DE9BE3FBF68A Q36199790-2A0E868C-0AC8-4D3E-8FBC-FF8B497E3CA5 Q36366356-3C2CCCAD-7BAB-44DD-8FFC-5AA96EDAA682 Q36862339-A67C08BF-422C-484B-8E21-D33F26569065 Q37212712-C37CB3EB-748E-4BD7-976D-97898BCE1242 Q37848037-AA060D80-1B15-4D89-A535-AECCA1C32AF4 Q37999957-57DAB5B9-C674-4101-BE02-5E6D0DFF827C Q38056010-D8FF3067-3EE2-4806-9EE1-7B52563BDC13 Q38072108-F2698D01-FE73-45DA-BB86-0F73F2E405A9 Q38095526-D894EAE4-5724-4D73-8070-C807B551957C Q38100588-DC2B71A1-AD88-4666-9677-19B2A9624376 Q38163027-DB581B12-B5B7-4A48-8A83-531EC4A3D849 Q38172295-DD707CE8-99C8-4CF2-89D0-D58584C7952B Q38240941-B2388A76-04A9-41CD-A4A1-254F871B9A54 Q38244397-1D38A4B1-31DC-42DF-8F57-505E049B3725 Q38259728-C6C6BC4A-1444-46B2-B0EF-E081A46561C9 Q38613822-18BCD34A-93F0-421C-90B3-2FDAC411F298 Q38829923-473F5983-DEFA-439B-B77F-FEC041CD2482 Q38920614-3516E725-6CA6-469E-98C6-99A518BE31B2 Q38928383-200D94B4-8AEE-46B9-824B-940D68B8C2F6 Q39272596-03D6C775-0341-40A5-BDDE-868928FF42BC Q40362742-88987F87-3B19-4CA9-9C44-F9AA546866BB Q40533557-A2983A0C-434A-4C99-8993-2E01742AABF9 Q42177959-E973530F-55AF-4801-AFE5-8A7C866DA82A Q46400142-4F0643B7-B43A-4257-BB8A-2E3B1AD3DC28 Q55023498-589138CB-BD24-4E59-AEE4-4F109D75553D Q58030111-231DD9EB-BCCB-4DAF-A352-9D62F5567586

P2860

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

http://www.wikidata.org/entity/Q36950813

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Discordance between serum card ...... d with immune modulatory drugs

@en

type

label

Discordance between serum card ...... d with immune modulatory drugs

@en

prefLabel

Discordance between serum card ...... d with immune modulatory drugs

@en

P1433

Q36950813-460DE42A-7FE3-46D3-BA93-058BD3CAC57D

P1476

Q36950813-6B1BD843-A409-4708-8030-2728ABB0F78B

P2093

Q36950813-1119240D-5403-4DC3-BE47-4DC5B45254B3

Q36950813-16EB2BE0-3AB2-4BD4-BB3C-F53CF704C96B

Q36950813-53638705-8CEE-40F4-9E12-FD1C111BB7CD

Q36950813-665E888C-E07F-4616-871D-C3343F086765

Q36950813-A84B360F-A3D7-44BE-BBC1-6141F5BE34A7

Q36950813-C4B10CC3-8A57-441F-ACC8-6AC7CB3A34E3

P2860

Q36950813-03D2B176-45D4-49A4-AB44-4C2F77A845C7

Q36950813-4D131D81-B6C9-4DB7-A164-089C5B7D56B5

Q36950813-4E1C7AF9-D4EA-4A7F-AA9C-999A347F2152

Q36950813-542A5CAD-0217-454C-A5EC-C2329FCC8A3E

Q36950813-CD931046-6447-43EB-B77C-EFF52872739C

Q36950813-DE5A92F2-3824-4B67-9FAC-D52D0E8C4D93

Q36950813-F2C68958-70D3-4354-8642-ECF0C1ED06FF

Q36950813-F5038117-8004-4225-A39A-1E67F01CE8AC

P304

Q36950813-43C9A118-556A-4BE5-BF7C-8141253D328B

P31

Q36950813-EFE0312A-865B-4258-9051-8868F2C398F7

P356

Q36950813-017FC329-56D3-490E-944B-10DDF54A78B5

P433

Q36950813-B15765EF-F322-4BAB-9ED6-3A14BB18FFC8

P478

Q36950813-E0631FC7-F597-443E-BE4D-37AA7502A4AC

P50

Q36950813-145C23B1-1774-49F2-A366-5FA1A647165C

Q36950813-62C6587C-BDBF-4B33-BD68-D97C6DD03AD8

Q36950813-A4899205-4EE2-45D5-B0D4-8FF883905DED

Q36950813-C2E7EEAE-67D8-4949-845C-03BE8F959516

Q36950813-CCD211A2-8BD0-45C8-AFE5-3C2760CB7B0F

Q36950813-D784DF7D-AF86-4A83-8444-5BBF5126DDC1

Q36950813-EE70D700-9359-4465-95FB-F865D9A3D00B

Q36950813-F56BB4E3-A41B-446B-B2DA-860A71D63C51

P577

Q36950813-F3F48A4D-EBE1-4AB6-BE6F-1F5438613E1B

P5875

Q36950813-C91A311D-6D9A-4277-A622-2CFC79049D59

P698

Q36950813-7D73AEF2-095F-44D9-B0A7-DAB52BACAD15

P921

Q36950813-A6DC233C-5505-44EE-8051-FADB29B27945

P932

Q36950813-8080720A-BD86-4DE7-B177-4FA73E17B0DA

P356

P1433

American Journal of Hematology

P1476

Discordance between serum card ...... d with immune modulatory drugs

@en

P2093

Frances Buadi

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Kristen Detweiler-Short

http://www.w3.org/2001/XMLSchema#string

Nelson Leung

http://www.w3.org/2001/XMLSchema#string

Shaji K Kumar

http://www.w3.org/2001/XMLSchema#string

Stephen Zeldenrust

http://www.w3.org/2001/XMLSchema#string

P2860

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

P304

757-759

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.21822

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Stephen J Russell

S. Vincent Rajkumar

Suzanne R Hayman

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46429311

http://www.w3.org/2001/XMLSchema#string

P698

20872958

http://www.w3.org/2001/XMLSchema#string

P921

P932

3691013

http://www.w3.org/2001/XMLSchema#string